Compare REBN & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REBN | BDRX |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 1.6M |
| IPO Year | 2017 | 2015 |
| Metric | REBN | BDRX |
|---|---|---|
| Price | $1.15 | $0.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 123.3K | ★ 7.2M |
| Earning Date | 04-22-2026 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,094,628.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.54 | N/A |
| 52 Week Low | $0.67 | $0.60 |
| 52 Week High | $2.95 | $11.88 |
| Indicator | REBN | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 37.86 |
| Support Level | $0.91 | $0.61 |
| Resistance Level | $2.02 | $1.58 |
| Average True Range (ATR) | 0.14 | 0.19 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 87.50 | 8.83 |
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is a company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in two reportable segments: Reborn Coffee, which includes both the wholesale and retail sales of coffee, water, and other beverages, and Reborn Logistics, which provides freight forwarding services.
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.